现代医药卫生2016，Vol.32Issue(7)：986-989,992,5.DOI:10.3969/j.issn.1009-5519.2016.07.009
造血干细胞移植治疗急性髓系白血病40例临床观察
Clinical observation on hematopoietic stem cell transplantation for treating 40 cases of acute myeloid leukemia
叶珂 1廖明燕 2唐晓琼 2王利 2张红宾 2肖青 2刘林1
作者信息
- 1. 重庆医科大学，重庆400016
- 2. 重庆医科大学附属第一医院血液科，重庆400042
- 折叠
摘要
Abstract
Objective To investigate the clinical efficacy and related complications of hematopoietic stem cell transplantation (HSCT) for treating acute myeloid leukemia(AML). Methods Forty patients with AML receiving HSCT in our hospital during 2011-2014 were selected and performed the analysis in the aspects of hematopoietic reconstruction ,curative effect follow up and total survival rate. Results Among 40 cases of AML,38 cases were succeeded in HSCT,In the cases of auto-HSCT and allo-HSCT, the median time of neutrophils series reconstruction was 12 d and 14 d respectively ,the macronucleus series reconstruction was 14 d and 20 s respectively;during follow up for 1-47 months,27cases(67.5%) were non-disease survival,6 cases were recurred, including 2 cases of auto-HSCT and 4 cases of allo-HSCT [refractory recurrence in 2 cases and-HSCT and non-refractory recurrence in 2 cases;in 7 cases of hi-HSCT,6 cases were succeeded. The overall survival(OS) of cases receiving auto-HSCT was 85.7%and the disease free survival(DFS) rate was78.6%,OS of the cases receiving allo-HSCT was 65.4%and their DFC was 61.5%,OS had no statistical difference between the two groups(P=0.183). Conclusion Auto-HSCT can serve as the consolidation therapy without donor after complete remission HSCT in the AML patients,allo-HSCT has low recurrence rate,most of patients can obtain clinical cure,but hi-HSCT also is relatively safe and effective selection for the AML patients without consistent donor.关键词
白血病,髓样,急性/移植物抗宿主病/造血干细胞移植/存活率/单倍性Key words
Leukemia,myeloid,acute/Graft vs host disease/Hematopoietic stem cell transplantation/Survival rate/Haploidy引用本文复制引用
叶珂,廖明燕,唐晓琼,王利,张红宾,肖青,刘林..造血干细胞移植治疗急性髓系白血病40例临床观察[J].现代医药卫生,2016,32(7):986-989,992,5.
